Jefferies Financial Group Inc. Purchases 560 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Jefferies Financial Group Inc. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% in the third quarter, Holdings Channel.com reports. The firm owned 20,300 shares of the biopharmaceutical company’s stock after purchasing an additional 560 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $15,393,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of REGN. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at about $5,682,636,000. State Street Corp grew its holdings in shares of Regeneron Pharmaceuticals by 3.6% during the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Regeneron Pharmaceuticals by 2.8% during the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after purchasing an additional 32,158 shares during the last quarter. Amundi increased its stake in shares of Regeneron Pharmaceuticals by 27.5% in the first quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock valued at $780,210,000 after buying an additional 217,892 shares during the period. Finally, Legal & General Group Plc acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $473,872,000. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on REGN shares. Sanford C. Bernstein raised their price objective on shares of Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the company a “market perform” rating in a report on Monday, November 2nd. Leerink Partners boosted their target price on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the stock a “market perform” rating in a report on Monday, November 2nd. Robert W. Baird boosted their target price on shares of Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Finally, Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $898.97.

Regeneron Pharmaceuticals Stock Up 4.7%

Shares of REGN opened at $959.41 on Thursday. The stock’s 50-day moving average price is $811.95 and its two-hundred day moving average price is $745.49. Regeneron Pharmaceuticals, Inc. has a 12 month low of $591.52 and a 12 month high of $991.73. The company has a market capitalization of $99.25 billion, a PE ratio of 21.18, a PEG ratio of 1.21 and a beta of 0.10. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter in the prior year, the firm posted $11.83 earnings per share. The business’s quarterly revenue was up 36.3% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be issued a $0.94 dividend. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.30%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, insider Andrew Murphy sold 4,147 shares of the firm’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christine Poon sold 7,830 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the completion of the transaction, the director owned 5,219 shares in the company, valued at $5,057,680.71. This trade represents a 60.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 27,028 shares of company stock valued at $25,025,950 over the last three months. Insiders own 6.97% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

These are some of the REGN headlines that stood out recently:

• Positive Sentiment: Regeneron collaborator Alnylam reported first-in-human results for CIDEBsiRNA in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD). A single dose rapidly normalized liver fat and improved markers of liver injury, providing encouraging early evidence for a potential treatment opportunity. Article: Alnylam collaborator Regeneron advances CIDEBsiRNA with promising first-in-human results
• Positive Sentiment: Soleo Health was selected as a specialty-pharmacy partner for Pasatru (garetosmab), Regeneron’s recently approved treatment for adults with the rare disorder fibrodysplasia ossificans progressiva. The partnership may support the drug’s distribution and patient access, although no sales impact was specified. Article: Soleo Health selected as a specialty pharmacy partner for Pasatru
• Neutral Sentiment: A Zacks article characterized REGN as a long-term value stock, but the summary provided no new company-specific developments or valuation details that would clearly explain near-term trading. Article: Why Regeneron is a top value stock for the long term

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.